EHS
EHS

Capecitabine related neurotoxicity: Clinical and radiologic features


    • Wilke H.

    Future treatment options with capecitabine in solid tumours.

    Eur. J. Cancer. 2002; 38: S21-S25

    • Niemann B.
    • Rochlitz C.
    • Herrmann R.
    • Pless M.

    Toxic encephalopathy induced by capecitabine.

    Oncology 2004. 2004; 66: 331-335

    • Renouf D.
    • Gill S.

    Capecitabine-induced cerebellar toxicity.

    Clin. Colorectal Cancer. 2006; 6: 70-71

    • Sengupta S.
    • Benkers T.
    • Blitstein M.
    • Palmer E.
    • Plotkin S.R.
    • Abramson J.S.

    Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma.

    Clin. Lymphoma, Myeloma & Leukemia. 2014; 14: e111-e113

    • Fantini M.
    • Gianni L.
    • Tassinari D.
    • Nicoletti S.
    • Possenti C.
    • Drudi F.
    • Sintini M.
    • Bagli L.
    • Tamburini E.
    • Ravaioli A.

    Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.

    J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract. 2011; 17: 288-291

    • Lyros E.
    • Walter S.
    • Keller I.
    • Papanagiotou P.
    • Fassbender K.

    Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology.

    Neurotoxicology. 2014; 42: 8-11

    • Monti M.
    • Barone D.
    • Amadori E.
    • Bartolini G.
    • Ruscelli S.
    • Frassineti G.L.

    Posterior reversible encephalopathy syndrome: a rare neurotoxicity after capecitabine.

    J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract. 2020; 26: 1795-1801

    • Nicoletti T.
    • Spagni G.
    • Luigetti M.
    • Iorio R.

    Teaching NeuroImages: transient mutism associated with splenium lesion in capecitabine-induced leukoencephalopathy.

    Neurology. 2019; 92: e1000-e1001https://doi.org/10.1212/WNL.0000000000007012

    • Endo A.
    • Yoshida Y.
    • Nakashima R.
    • Takahashi N.
    • Tanabe K.

    Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.

    Int. Heart J. 2013; 54: 417-420

    • Yoshimura K.
    • Tokunaga S.
    • Daga H.
    • Inoue M.

    Capecitabine-induced leukoencephalopathy.

    Intern. Med. 2019; 58: 621-622

    • Tan M.B.-W.
    • McAdory L.E.

    Capecitabine-induced leukoencephalopathy involving the bilateral corticospinal tracts.

    J. Radiol. Case Rep. 2016; 10: 1-10

    • Couch L.S.B.
    • Groteluschen D.L.
    • Stewart J.A.
    • Mulkerin D.L.

    Capecitabine-related neurotoxicity presenting as trismus.

    Clin. Colorectal Cancer. 2003; 3: 121-123

    • Videnovic A.
    • Semenov I.
    • Chua-Adajar R.
    • Baddi L.
    • Blumenthal D.T.
    • Beck A.C.
    • Simuni T.
    • Futterer S.
    • Gradishar W.
    • Tellez C.
    • Raizer J.J.

    Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.

    Neurology. 2005; 65 (discussion 1685): 1792-1794

    • Godinho J.
    • Casa-Nova M.
    • Mesquita T.
    • Baptista M.J.
    • Araújo F.
    • Vale J.
    • Passos Coelho J.L.

    Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment.

    J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract. 2019; 25: 497-501

    • Gounaris I.
    • Ahmad A.

    Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.

    J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract. 2010; 16: 277-279

    • Saif M.W.

    Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.

    Anti-Cancer Drugs. 2019; 30: 431-434

    • Formica V.
    • Leary A.
    • Cunningham D.
    • Chua Y.J.

    5-fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma.

    Cancer Chemother. Pharmacol. 2006; 58: 276-278

    • Femia G.
    • Hardy T.A.
    • Spies J.M.
    • Horvath L.G.

    Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.

    Asia-Pacific J. Clin. Oncol. 2012; 8: 115-122

    • Ngeow J.Y.Y.
    • Prakash K.M.
    • Chowbay B.
    • Quek S.T.
    • Choo S.-P.

    Capecitabine-induced oromandibular dystonia: a case report and literature review.

    Acta Oncol. 2008; 47: 1161-1165

    • Tang K.H.

    Oxaliplatin-induced posterior reversible encephalopathy syndrome with isolated involvement of pons.

    J. Cancer Res. Ther. 2015; 11: 1022

    • Chansky K.
    • Benedetti J.
    • Macdonald J.S.

    Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.

    Cancer. 2005; 103: 1165-1171

    • Ogata Takatsugu
    • Satake Hironaga
    • Ogata Misato
    • Hatachi Yukimasa
    • Yasui Hisateru

    Oxaliplatin-induced Hyperammonemic encephalopathy in a patient with metastatic pancreatic Cancer: a case report.

    Case Rep. Oncol. 2017; 10: 885-889

    • Monti Manlio
    • Barone Domenico
    • Amadori Elena
    • Bartolini Giulia
    • Ruscelli Silvia
    • Frassineti Giovanni Luca

    Posterior reversible encephalopathy syndrome: a rare neurotoxicity after capecitabine.

    J. Oncol. Pharm. Pract. 2020 Oct; 26: 1795-1801

    • Starkey Jay
    • Kobayashi Nobuo
    • Numaguchi Yuji
    • Moritani Toshio

    Cytotoxic lesions of the Corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations.

    Radiographics. 2017; 37: 562-576

    • Cassidy J.
    • Twelves C.
    • Van Cutsem E.
    • Hoff P.
    • Boyer M.
    • Bugat R.
    • et al.

    First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profifile compared with intravenous 5-fluorouracil/leucovorin.

    Ann. Oncol. 2002; 13: 75

    • Franco D.A.
    • Greenberg H.S.

    5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.

    Neurology. 2001; 56: 110-112

    • Kim Y.
    • Kim J.W.

    Toxic encephalopathy.

    Saf. Health Work. 2012; 3: 243-256

    • Milano G.
    • Ferrero J.-M.
    • François E.

    Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.

    Br. J. Cancer. 2004 Aug 16; 91: 613-617

    • Louie S.G.
    • Ely B.
    • Lenz H.J.
    • et al.

    Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).

    Br. J. Cancer. 2013; 109: 1744-1749https://doi.org/10.1038/bjc.2013.517

    • Milano G.
    • Etienne M.C.
    • Cassuto-Viguier E.
    • et al.

    Influence of sex and age on fluorouracil clearance.

    J. Clin. Oncol. 1992; 10: 1171-1175https://doi.org/10.1200/JCO.1992.10.7.1171



  • Source link

    EHS
    Back to top button